US equities |
NVDA $239.81 ▲+2.50% SPCX $169.69 ▲+6.75% MU $1,060.61 ▼-1.33% TSLA $380.94 ▲+2.79% SNDK $1,693.50 ▼-1.54% MSFT $528.40 ▲+2.10% INTC $116.49 ▼-2.38% META $743.71 ▲+2.15%
FinancialContent

Intersect ENT, Inc. - Common Stock (NQ:XENT)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intersect ENT, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
News headline image
Earnings Scheduled For May 10, 2021 ↗
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... 
Via Benzinga
News headline image
Intersect ENT to Participate at Upcoming Investor Conferences
From Intersect ENT, Inc.
Via Business Wire
News headline image
Intersect ENT Announces Appointment of New Vice President of Sales
From Intersect ENT, Inc.
Via Business Wire
News headline image
Intersect ENT Announces Date Change for First Quarter 2021 Financial Results Announcement
From Intersect ENT, Inc.
Via Business Wire
News headline image
EXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL® Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation
From Intersect ENT, Inc.
Via Business Wire
News headline image
Intersect ENT to Report First Quarter 2021 Financial Results
From Intersect ENT, Inc.
Via Business Wire
< Previous 1 2 Next >